Compare Autozone Inc (AZO) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Autozone Inc vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? Autozone Inc trades at $3,042 (market cap $50.09B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B). The key difference: Autozone Inc is far larger — about 5.3× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Autozone Inc nearer its low. Which is the better fit depends on your goals.
| AZO | BIO | |
|---|---|---|
Market Cap | $50.09B | $9.39B |
Sector | Consumer Cyclical | Health |
52-Week High | $4.35K | $354.54 |
52-Week Low | $2.92K | $241.71 |
Enterprise Value | $62.46B | $9.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AutoZone (AZO) trades at $3,127.29, up 1.88% recently, with a bullish technical signal and strong analyst support. Revenue grew to $18.94B in 2025, though net income margin dipped to 13.19%. The company maintains robust cash flow from operations and recently authorized a $1.5B stock buyback, signaling confidence. Key resistance lies near $3,160, with support at $3,063.
Outlook remains positive with 73% analyst buy ratings and a $3,730 consensus price target, implying ~19% upside. Risks include margin pressure from rising costs and competitive threats. Earnings beats in recent quarters support growth, but investors should monitor execution on international expansion and capex efficiency.
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Autozone Inc
AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.
Read more on AZO →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
